Acrivon Therapeutics Inc
ACRV
Get informed when a big investor buys or sells
+ FollowMarket Cap$91.17M
Close$
$1.01
52.7% downside
Current Fair Value
52.7% downsideOvervalued by 52.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $91.17 Million |
|---|---|
| Enterprise Value | $51.87 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.02 |
| Beta | 1.86 |
| Outstanding Shares | 41,841,887 |
Return
| Return on Equity | -85.65% |
|---|---|
| Return on Assets | -74.91% |
| Return on Invested Capital | -94.41% |
Valuation & Multiples
| P/E Ratio | -1.13 |
|---|---|
| PEG | 7.82 |
| Price to Sales | - |
| Price to Book Ratio | 1.07 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.63 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
$386,333
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.45
Average shareholder expectationRevenue Estimate
$504,333
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 41.93%▼ 6.40% |
|---|---|
| Total Invested | $22.57M▼ 49.68% |
| Investors Holding | 43▼ 5.00% |
ESG Score
No data